Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Hiroyuki Okada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2814-7146; OpenAlex author ID A5001121988. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 10

  1. Association of screening tool scores with overall survival in older patients with unresectable gastrointestinal or biliary pancreatic cancer: A retrospective s… Co-author DOI 10.1016/j.jgo.2024.101714↗
  2. Effectiveness of an Oral Elemental Diet for Patients With Unresectable Pancreatic Cancer: a Prospective Cohort Study Last author DOI 10.21203/rs.3.rs-1244457/v1↗
  3. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Last author DOI 10.1007/s10620-019-06006-6↗
  4. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Last author DOI 10.1007/s00535-019-01586-6↗
  5. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1080/15384047.2019.1638685↗
  6. Diagnostic Ability of Convex-Arrayed Endoscopic Ultrasonography for Major Vascular Invasion in Pancreatic Cancer. Last author DOI 10.5946/ce.2018.163↗
  7. Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients. Co-author DOI 10.1007/s00795-018-0197-8↗
  8. Preoperative Detection of Tumor Seeding after Endoscopic Ultrasonography-guided Fine Needle Aspiration for Pancreatic Cancer. Last author DOI 10.2169/internalmedicine.0321-17↗
  9. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29364↗
  10. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.009↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hironari Kato · 10 shared papers, 2012–2024 · strength 0.94
  2. Shigeru Horiguchi · 6 shared papers, 2019–2024 · strength 0.68
  3. Kazuyuki Matsumoto · 5 shared papers, 2018–2020 · strength 0.47
  4. Daisuke Uchida · 3 shared papers, 2019–2020 · strength 0.27
  5. Kazuhiro Nouso · 4 shared papers, 2012–2020 · strength 0.26
  6. Hideaki Kinugasa · 3 shared papers, 2015–2020 · strength 0.23
  7. Soichiro Ako · 2 shared papers, 2019–2020 · strength 0.19
  8. Shinichiro Muro · 2 shared papers, 2019–2020 · strength 0.19
  9. Shoko Inoo · 1 shared paper, 2024 · strength 0.17
  10. Motoyuki Otsuka · 1 shared paper, 2024 · strength 0.17
  11. Hitomi Himei · 1 shared paper, 2022 · strength 0.15
  12. Ryosuke Sato · 1 shared paper, 2022 · strength 0.15
  13. Ryo Harada · 1 shared paper, 2022 · strength 0.15
  14. Yuki Fujii · 1 shared paper, 2019 · strength 0.09
  15. Hiroyuki Terasawa · 1 shared paper, 2019 · strength 0.09
  16. Yuzo Umeda · 1 shared paper, 2019 · strength 0.08
  17. Ryuichi Yoshida · 1 shared paper, 2019 · strength 0.08
  18. Koichiro Tsutsumi · 2 shared papers, 2012–2015 · strength 0.07
  19. Kazuhide Yamamoto · 2 shared papers, 2012–2015 · strength 0.07
  20. Tadashi Yoshino · 1 shared paper, 2018 · strength 0.07
  21. Shizuma Omote · 1 shared paper, 2018 · strength 0.07
  22. Koji Miyahara · 1 shared paper, 2015 · strength 0.05
  23. Ken Hirao · 1 shared paper, 2012 · strength 0.03
  24. Hirofumi Kawamoto · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.